SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q4 2021 vs. Q3 2021
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 1 | 34 | +33 |
| Shares | 60.0K | 3.10M | +3.04M (+5,060.6%) |
| Value | $605.0K | $25.4M | +$24.8M (+4,103.6%) |
New holders (34)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Tudor Investment Corp Et Al | 60,000 | $605.0K |